Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX with regorafenib using chemotherapy holidays after surgery for high-risk biliary tract cancer
ChiCTR2200060670Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of regorafenib, gemcitabine, oxaliplatin and capecitabine in biliary cancer (3 cohorts), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Chemotherapy completion and Recurrence-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
regorafenibgemcitabineoxaliplatincapecitabine
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2200060670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060670.